Tetraphase Pharmaceuticals (TTPH) Rating Increased to Hold at Zacks Investment Research

Tetraphase Pharmaceuticals (NASDAQ:TTPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

TTPH has been the topic of a number of other research reports. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. BMO Capital Markets raised their target price on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a report on Wednesday, October 4th. Finally, ValuEngine lowered Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $15.15.

Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.51 on Friday. Tetraphase Pharmaceuticals has a fifty-two week low of $3.57 and a fifty-two week high of $9.93. The firm has a market capitalization of $334.71, a P/E ratio of -2.28 and a beta of 2.51.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. During the same quarter last year, the company earned ($0.58) earnings per share. The company’s revenue for the quarter was up 355.6% on a year-over-year basis. equities analysts forecast that Tetraphase Pharmaceuticals will post -2.88 earnings per share for the current fiscal year.

In other Tetraphase Pharmaceuticals news, Director L Patrick Gage purchased 3,880 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the sale, the insider now owns 8,750 shares in the company, valued at $52,762.50. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in Tetraphase Pharmaceuticals during the third quarter worth $195,000. California State Teachers Retirement System increased its position in Tetraphase Pharmaceuticals by 20.1% in the third quarter. California State Teachers Retirement System now owns 80,471 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 13,451 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Tetraphase Pharmaceuticals by 32.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock worth $9,998,000 after buying an additional 360,552 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Tetraphase Pharmaceuticals by 67.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 217,079 shares of the biopharmaceutical company’s stock worth $1,485,000 after buying an additional 87,398 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in Tetraphase Pharmaceuticals in the third quarter worth $7,915,000. Institutional investors and hedge funds own 58.15% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was posted by Week Herald and is owned by of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://weekherald.com/2018/01/14/tetraphase-pharmaceuticals-ttph-rating-increased-to-hold-at-zacks-investment-research.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply